Pharmacokinetics and pharmacodynamics of norfluoxetine in rats: Increasing extracellular serotonin level in the frontal cortex

Pharmacology Biochemistry and Behavior

Volumn 92, Issue 3, 2009, Pages 469-473

  Qu, Ying ^a   Aluisio, Leah ^a   Lord, Brian ^a   Boggs, Jamin ^a   Hoey, Kenway ^a   Mazur, Curt ^a   Lovenberg, Timothy ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Fluoxetine; In vivo microdialysis; Norfluoxetine; Pharmacodynamic; Pharmacokinetic; Serotonin

Indexed keywords

FLUOXETINE; NORFLUOXETINE; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG RETENTION; FRONTAL CORTEX; LIQUID CHROMATOGRAPHY; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY;

ANIMALS; CHROMATOGRAPHY, LIQUID; FLUOXETINE; FRONTAL LOBE; MALE; MICRODIALYSIS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; TANDEM MASS SPECTROMETRY;

ANIMALIA; RATTUS;

EID: 62549141446     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2009.01.023     Document Type: Article

References (35)

1. Altamura A.C., Moro A.R., and Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 26 (1994) 201-214
2. Barbier A.J., Aluisio L., Lord B., Qu Y., Wilson S.J., Boggs J.D., et al. Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. Eur J Pharmacol 576 (2007) 43-54
3. Baumann P., and Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol 10 Suppl 1 (1995) 15-21
4. Benfield P., Clissold S.P., and Brogden R.N. Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. Drugs 31 (1986) 376-429
5. Beyer C.E., Boikess S., Luo B., and Dawson L.A. Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study. J Psychopharmacol 16 (2002) 297-304
6. Blier P., and de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15 (1994) 220-226
7. Boothman L.J., Mitchell S.N., and Sharp T. Investigation of the SSRI augmentation properties of 5-HT(2) receptor antagonists using in vivo microdialysis. Neuropharmacology 50 (2006) 726-732
8. Bourdeaux R., Desor D., Lehr P.R., Younos C., and Capolaghi B. Effects of fluoxetine and norfluoxetine on 5-hydroxytryptamine metabolism in blood platelets and brain after administration to rats. J Pharm Pharmacol 50 (1998) 1387-1392
9. Bymaster F.P., Zhang W., Carter P.A., Shaw J., Chernet E., Phebus L., et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) 160 (2002) 353-361
10. Caccia S., Cappi M., Fracasso C., and Garattini S. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology (Berl) 100 (1990) 509-514
11. Fuller R.W. Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci 55 (1994) 163-167
12. Fuller R.W. Serotonin uptake inhibitors: uses in clinical therapy and in laboratory research. Prog Drug Res 45 (1995) 167-204
13. Fuller R.W., Snoddy H.D., Krushinski J.H., and Robertson D.W. Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropharmacology 31 (1992) 997-1000
14. Gardier A.M., Lepoul E., Trouvin J.H., Chanut E., Dessalles M.C., and Jacquot C. Changes in dopamine metabolism in rat forebrain regions after cessation of long-term fluoxetine treatment: relationship with brain concentrations of fluoxetine and norfluoxetine. Life Sci 54 (1994) PL51-PL56
15. Goodnick P.J. Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet 27 (1994) 307-330
16. Gram L. Fluoxetine. N Engl J Med 331 (1994) 1354-1361
17. Hiemke C., and Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 85 (2000) 11-28
18. Jacobs B.L., and Azmitia E.C. Structure and function of the brain serotonin system. Physiol Rev 72 (1992) 165-229
19. Jouvet M., and Pujol J.F. Effects of central alterations of serotoninergic neurons upon the sleep-waking cycle. Adv Biochem Psychopharmacol 11 (1974) 199-209
20. Kobayashi T., Hayashi E., Shimamura M., Kinoshita M., and Murphy N.P. Neurochemical responses to antidepressants in the prefrontal cortex of mice and their efficacy in preclinical models of anxiety-like and depression-like behavior: a comparative and correlational study. Psychopharmacology 197 (2008) 567-580
21. Koch S., Perry K.W., Nelson D.L., Conway R.G., Threlkeld P.G., and Bymaster F.P. R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study. Neuropsychopharmacology 27 (2002) 949-959
22. Mandrioli R., Forti G.C., and Raggi M.A. Fluoxetine metabolism and pharmacological interactions: the role of cytochrome p450. Curr Drug Metab 7 (2006) 127-133
23. Masand P.S., and Gupta S. Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry 7 (1999) 69-84
24. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1997)
25. Portas C.M., Bjorvatn B., Fagerland S., Gronli J., Mundal V., Sorensen E., et al. On-line detection of extracellular levels of serotonin in dorsal raphe nucleus and frontal cortex over the sleep/wake cycle in the freely moving rat. Neuroscience 83 (1998) 807-814
26. Qu Y., Chang L., Klaff J., Seemann R., and Rapoport S.I. Imaging brain phospholipase A2-mediated signal transduction in response to acute fluoxetine administration in unanesthetized rats. Neuropsychopharmacology 28 (2003) 1219-1226
27. Qu Y., Chang L., Klaff J., Seemann R., Greenstein D., and Rapoport S.I. Chronic fluoxetine upregulates arachidonic acid incorporation into the brain of unanesthetized rats. Eur Neuropsychopharmacol 16 (2006) 561-571
28. Rocher C., Bert L., Robert F., Trouvin J.H., Renaud B., Jacquot C., et al. Microdialysis monitoring of variations in extracellular levels of serotonin, GABA and excitatory amino acids in the frontal cortex of awake rats in response to a single peripheral or central administration of dexfenfluramine. Brain Res 737 (1996) 221-230
29. Rueter L.E., and Jacobs B.L. Changes in forebrain serotonin at the light-dark transition: correlation with behaviour. Neuroreport 7 (1996) 1107-1111
30. Rueter L.E., Fornal C.A., and Jacobs B.L. A critical review of 5-HT brain microdialysis and behavior. Rev Neurosci 8 (1997) 117-137
31. Rusak B., and Bina K.G. Neurotransmitters in the mammalian circadian system. Annu Rev Neurosci 13 (1990) 387-401
32. Stahl S.M. Mechanism of action of serotonin selective reuptake inhibitors, serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord 51 (1998) 215-235
33. Tulloch I.F., and Johnson A.M. The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. J Clin Psychiatry 53 (1992) 7-12 Suppl
34. Wong D.T., Bymaster F.P., and Engleman E.A. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 57 (1995) 411-441
35. Wright I.K., Garratt J.C., and Marsden C.A. Effects of a selective 5-HT2 agonist, DOI, on 5-HT neuronal firing in the dorsal raphe nucleus and 5-HT release and metabolism in the frontal cortex. Br J Pharmacol 99 (1990) 221-222